Dexfenfluramine for weight gain secondary to psychotropics
Prakash S. Masand, Sanjay Gupta
Abstract
Open-access reader
Prakash S. Masand, Sanjay Gupta
Abstract
Open-access reader
We describe the use of dexfenfluramine (Redux) in six patients with mood disorders (bipolar disorder = 3; major depression = 3) who developed significant weight gain as a result of their psychotropics. All patients were females with an age range of 27-58 years. The duration of the trial varied from 3 to 20 weeks, with the dexfenfluramine dosage being 15 mg twice daily. Weight loss ranged from 2 to 23 pounds. None of the patients had any evidence of primary pulmonary hypertension or serotonin syndrome, despite being on serotonergic agents such as fluoxetine, paroxetine, and sertraline.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
We describe the use of dexfenfluramine (Redux) in six patients with mood disorders (bipolar disorder = 3; major depression = 3) who developed significant weight gain as a result of their psychotropics. All patients were females with an age range of 27-58 years. The duration of the trial varied from 3 to 20 weeks, with the dexfenfluramine dosage being 15 mg twice daily. Weight loss ranged from 2 to 23 pounds. None of the patients had any evidence of primary pulmonary hypertension or serotonin syndrome, despite being on serotonergic agents such as fluoxetine, paroxetine, and sertraline.
Key concepts: Dexfenfluramine, Paroxetine, Sertraline, Fluoxetine, Depression (economics), Medicine, Weight gain, Psychiatry